---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-011309"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T19:08:18.538050+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Clene: 96% of CNM-Au8-treated MS patients with vision gains also showed MRI remyelination evidence

## Summary
- 96% of LCLA visual responders had improved MRI DTI metrics (AD/MTR), confirming remyelination and neuronal repair.
- 91% of LCLA visual responders showed multi-focal VEP improvements (latency/amplitude), indicating functional recovery.
- 98% of SDMT cognitive responders exhibited corresponding MRI DTI improvements, linking cognitive gains to repair.
- Data from long-term open-label extension of Phase 2 VISIONARY-MS trial presented at AAN 2025 Late-Breaking Science Session.
- Clene plans to confirm findings in a global Phase 3 trial for CNM-Au8 in multiple sclerosis.

## SEC filing metadata
- accession: 0001437749-25-011309
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774925011309/0001437749-25-011309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774925011309/clnn20250407_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-011309
- JSON: https://secwatch.observer/filing/0001437749-25-011309.json
- Plain text: https://secwatch.observer/filing/0001437749-25-011309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.